Xencor Appoints Raymond Deshaies to Board of Directors to Bolster Drug Development Efforts
PorAinvest
sábado, 2 de agosto de 2025, 4:21 pm ET1 min de lectura
AMGN--
Prior to joining Xencor, Deshaies served as senior vice president of global research at Amgen Inc., where he oversaw all research activities, including the nomination of over 50 clinical candidates, expansion of Amgen’s capabilities for discovering and optimizing multispecific drug candidates, and application of generative protein design to biologics discovery. He completed his tenure at Amgen as a distinguished fellow.
Deshaies’ appointment is expected to bolster Xencor’s efforts in advancing its pipeline of XmAb drug candidates through clinical development. Xencor’s XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action.
“Ray holds a deep understanding of biological mechanisms and has a long track-record of translating cutting-edge scientific insights into transformative medicines for patients,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. “We welcome Ray to our Board and look forward to his contributions as we advance our pipeline of novel XmAb® drug candidates through clinical development.”
Analysts have rated XNCR stock as a Buy with a $38.00 price target [2].
References:
[1] https://www.businesswire.com/news/home/20250731140486/en/Xencor-Appoints-Raymond-Deshaies-Ph-D-to-Board-of-Directors
[2] https://www.stocktitan.net/news/XNCR/xencor-appoints-raymond-deshaies-ph-d-to-board-of-p7wuet5jeggr.html
XNCR--
Xencor has appointed Raymond Deshaies to its board of directors, bringing extensive experience in biotechnology and drug development. His appointment is expected to bolster Xencor's efforts in advancing its pipeline of XmAb drug candidates through clinical development. Analysts rate XNCR stock as a Buy with a $38.00 price target.
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, has appointed Raymond J. Deshaies, Ph.D., to its board of directors. Deshaies, a pioneering biochemist and cell biologist with over 25 years of experience in biotechnology and drug development, brings a wealth of expertise to the board.Prior to joining Xencor, Deshaies served as senior vice president of global research at Amgen Inc., where he oversaw all research activities, including the nomination of over 50 clinical candidates, expansion of Amgen’s capabilities for discovering and optimizing multispecific drug candidates, and application of generative protein design to biologics discovery. He completed his tenure at Amgen as a distinguished fellow.
Deshaies’ appointment is expected to bolster Xencor’s efforts in advancing its pipeline of XmAb drug candidates through clinical development. Xencor’s XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action.
“Ray holds a deep understanding of biological mechanisms and has a long track-record of translating cutting-edge scientific insights into transformative medicines for patients,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. “We welcome Ray to our Board and look forward to his contributions as we advance our pipeline of novel XmAb® drug candidates through clinical development.”
Analysts have rated XNCR stock as a Buy with a $38.00 price target [2].
References:
[1] https://www.businesswire.com/news/home/20250731140486/en/Xencor-Appoints-Raymond-Deshaies-Ph-D-to-Board-of-Directors
[2] https://www.stocktitan.net/news/XNCR/xencor-appoints-raymond-deshaies-ph-d-to-board-of-p7wuet5jeggr.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios